Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Target Price of $42.33 According to Analysts

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) has received an average recommendation of “Hold” from the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $42.33.

A number of equities research analysts have recently issued reports on the company. Lifesci Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 target price on the stock in a research note on Monday, August 10th. BTIG Research cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 10th. JonesTrading downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Finally, Raymond James Financial lowered Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday, August 10th.

Get Sionna Therapeutics alerts:

Get Our Latest Analysis on Sionna Therapeutics

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. sold 3,448,811 shares of Sionna Therapeutics stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $6.33, for a total transaction of $21,830,973.63. Following the completion of the sale, the director owned 3,448,812 shares of the company’s stock, valued at approximately $21,830,979.96. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP bought a new stake in shares of Sionna Therapeutics in the second quarter valued at approximately $686,000. AXQ Capital LP bought a new position in Sionna Therapeutics during the 2nd quarter worth $202,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Sionna Therapeutics by 9,056.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,622 shares of the company’s stock worth $467,000 after acquiring an additional 10,506 shares during the period. Wellington Management Group LLP bought a new position in Sionna Therapeutics during the 2nd quarter worth $1,644,000. Finally, Artia Global Partners LP acquired a new position in Sionna Therapeutics in the 2nd quarter valued at $5,267,000.

Sionna Therapeutics Stock Performance

Shares of SION stock opened at $4.09 on Thursday. The company has a market capitalization of $184.92 million, a price-to-earnings ratio of -1.88 and a beta of 1.00. The company has a 50-day simple moving average of $7.71 and a 200 day simple moving average of $29.58. Sionna Therapeutics has a 52 week low of $3.93 and a 52 week high of $54.97.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Sell-side analysts forecast that Sionna Therapeutics will post -2.54 EPS for the current year.

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics, Inc (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company is developing small-molecule therapies intended to address the underlying cause of CF by improving the production, processing, stability and function of defective CFTR proteins.

Sionna’s research platform is centered on CFTR modulators, including compounds designed to stabilize the CFTR protein’s nucleotide-binding domain 1 (NBD1).

Featured Articles

• Five stocks we like better than Sionna Therapeutics
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
• PBF Energy’s Stunning Rally Faces a Critical Test
• Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.